After a disappointing fiscal 2017 second-quarter, Medtronic PLC’s third-quarter results beat analysts’ projections and put the company on track to achieve its targets for 2017.
The company credited innovative products as well as the continued integration of Covidien Ltd. for driving overall revenue up 6% to $7.283bn and diluted earnings per-share up 10% to...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?